CEO / PRESIDENT
Turnaround Management ? Multi-National Business Development
M&A ? New Revenue Platforms
CHIEF ARCHITECT for the strategic plan and lead builder of new revenue platforms. Deal maker skilled at identifying growth opportunities and forward thinking positioning strategies, focusing on key technologies and core strengths, and understanding that change is survival and essential to the life and growth of the organization.
STRATEGY LEADER successful in revitalizing and growing businesses with an emphasis on the biopharmaceutical, life sciences, and high tech industries. Entrepreneurial visionary and inspiring leader with the established reputation of a ?hands-on? rainmaker with in-depth strategic and operating experience in public companies, turnarounds, M&A, and capital financing (equity and debt) of more than $100M including IPOs. Strengths include:
* Revenue Model Development
* Cost-Effective Marketing
* Thought Leadership and Focus
* Commercialization of Technology
* Global Collaboration / Partnerships
* Capital Formation / IPO
* P&L Control greater then $100M
* Talent Recruitment / Motivation
* Market Opportunity Identification
VALUE OFFERED:
> Demonstrated passion for creating strategy during change. Proven ability to provide the strategic focus, change leadership, and tools critical in the commercialization of technology and to attain standing as a self-sustaining, revenue generating business unit.
> Successful building and leading top tier, top talent management and technical teams to ensure solutions and success during change, maintaining an entrepreneurial spirit and overcoming resistance.
> Turn-around management experience in more than 30 portfolio companies in diverse industries including biopharmaceuticals, technology, and consumer products industries.
> Formed several high tech companies and led an international pharmaceutical chemical manufacturer through an IPO. Board Director experience including Chairman of a public company.
CAREER ACCOMPLISHMENTS
A BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY, 2001 to October 2006
A $7M contract services organization providing a full range of highly efficient, biopharmaceutical drug development outsourced services to biotech and large pharmaceutical companies
President / CEO / Board of Directors
Recruited by the Board of this R&D Company founded in 1996 upon proprietary, patented bioreactor technology, to refocus and drive revenue growth in an operation that had no existing revenue platform, no collaborations, and few investors. Within four years, accomplished the following:
* Transitioned the company from an R&D based organization to a revenue-producing large molecule drug development service platform. Created and spun off a drug development company as a separate business unit that focused exclusively on the emerging, profitable outsourcing in the biopharmaceutical industry ? a high demand and high growth sector.
* Redirected R&D away from bio-remediation applications and toward protein drug bio-production.
* Developed revenue generating service business based on a full service technology platform for protein drug development approaching positive EBITDA within 18 months.
* Secured $1M loan from North Carolina Biotechnology Center; relocated operations from Atlanta, GA to a purchased facility in Durham, North Carolina in 2003.
* Raised $40M in debt and equity and built cGMP (current Good Manufacturing Practices) biopharma development labs and Phase I Clinical Manufacturing operations.
* Negotiated collaborative agreements in India for contract bio-manufacturing and bio-generics. International clients include major pharmaceutical and biotechnology companies.
* Pursued and acquired 30 contracts, with clients ranging from major pharmaceutical companies to multi-national governments. Grew the revenue stream to $7M in two years, approaching positive cash flow.
By creating a drug development revenue stream, we established ?loner survivability? status for the company. In addition, this comprehensive drug development technology platform opened significant new market opportunities ? a pipeline for bio-manufacturing (CMO) opportunities; a crucial technology wedge for entering the emerging bio-generic markets; as well as a launch pad for the company?s proprietary bioreactor technology. My intrinsic understanding of the strategic impact of outsourcing in the drug industry future drove this company?s success.
A DEVELOPMENT PLATFORM COMPANY, Cambridge, MA 2000 to 2001
Interim President / CEO
Joined this R&D company engaged in the development of proprietary technology for In-silico predictive ADME-Tox response of small molecule drugs. Within a nine-month period, negotiated VC financing, established strategic collaborations, and negotiated sale of the company.
MANAGEMENT GROUP, Concord, MA 1992 to 2000
President / CEO / Board of Directors
Provided ?hands-on? turnaround management, developmental resources and interim leadership for more than 33 companies in crisis mode across all industries from high tech to chemical manufacturing, electrical equipment, metal fabrication, retail drug, industrial equipment manufacturing, and an auto dealership.
Averaging turnaround within 6 to 9 months; assessed efficiency and quality of current operations, created business plan, and led the restructure focused around the core technology and/or base business, and, in most instances, reestablished a steady flow of revenue in preparation for sale or merger. Maintained a culture of optimism and stabilized employee morale during a period of change, working closely with key decision makers and financial institutions.
Notable achievements:
* Refocused and streamlined operations for a $25M worldwide heavy equipment manufacturer and distributor on the verge of foreclosure. Within two and a half years turned around the company to today?s value of $50M through restructure. Identified key technologies and strengths, implemented cost effective marketing, while the Company expanded an international business base in Mexico, India, and Egypt.
* Turned around an overextended electric equipment manufacturer with international sales. Within nine months reduced losses by 50% and prepared the company for successful sale to a major competitor.
* Assumed management role and reversed downward trend of a Mercedes-Benz, Saab, and Subaru dealership facing bankruptcy. Within a three-year period ? reduced losses and set-up payment plans with creditors, rebuilt solid relationships with each franchise, and negotiated the sale of the franchise and its real estate ? resulting in a positive monetary gain for the owners.
A MEDICAL PRODUCTS COMPANY, Horsham, PA 1988 to 1992
COO
Recruited a sales, marketing, operation and quality assurance management team, including a CFO, to build a 25 member national distribution sales force and to oversee contract and pricing negotiations on foreign manufactured products for patient care.
* Launched several new products, effectively capturing significant market share from established global suppliers.
* Attained profitability after second year through knowledge and thought leadership, creativity, and strategic design.
A CHEMICALS MANUFACTURING COMPANY, New Brunswick, NJ 1982 to 1988
President / CEO / BOD
Founded this company after acquiring a closed pharmaceutical chemicals plant. Formed a chemicals manufacturing company. Secured all financing, including IPO. Negotiated manufacturing licenses for amino acids, antibiotics, growth promoters.
* Grew Cell Products from zero to 200 employees and $80M in sales.
* Sold the company to Squibb Pharmaceuticals in 1988.
BIOSCIENCES TECHNOLOGY AND SERVICES PROVIDER, Bedford, MA 1972 to 1981
Market Manager - Life Sciences
Marketed and sold directed at Life Science research and university markets.
EDUCATION
LEMOYNE COLLEGE, Syracuse, NY
Bachelors Degree - Chemistry
BOARD AFFILIATIONS
Chairman of the Board of Directors, a Chemicals Manufacturing Company
Board of Directors, a Biopharmaceutical Drug Development Company
Board of Directors, an R&D Company
Board of Directors, a Management Group |
